YOUR BUSINESS AUTHORITY
Springfield, MO
Bio-Kinetic, which designs and conducts Phase 1 clinical studies for pharmaceutical and biotechnology companies, will retain its name and become a wholly owned unit of QPS Holdings Inc. The Springfield company has a 240-bed facility at 1820 W. Mount Vernon St.
QPS is a contract research company providing testing services for preclinical and clinical research and development. With its acquisition of Bio-Kinetic, QPS will be able to take drug development beyond discovery and preclinical testing into Phase 1 research, according to a news release.
Bio-Kinetic was founded in 1994 by Dale Bourg and Dave Koenigsfeld and has since completed more than 400 clinical studies and enrolled approximately 11,000 volunteers, according to the release.
The acquisition is being structured as a merger, with Bio-Kinetic shareholders receiving membership interests in QPS Holdings. Private equity firms Argentum Capital Partners and First Analysis Corp. will become equity holders of QPS along with Bourg and Koenigsfeld.
“The acquisition of Bio-Kinetic will provide our clients with access to industry experts in LC/MS/MS, ELISA, biomarkers and genotyping – complex procedures that can provide immense value in the decision-making process while developing a compound,” Bourg, Bio-Kinetic’s CEO, said in a news release.
This story originally appeared in SBJ’s Dec. 7 free e-news Daily Update. Click here to register.
Nixa Superintendent Gearl Loden weighs in on A-F grade cards.
Thanksgiving staple recalled at Costco
HBA of Greater Springfield executive officer to retire
Warren Buffett donates $5.5B worth of Berkshire Hathaway shares
Transportation officials discuss $471M Forward 44 initiative
Monday Morning Business Leads: Nov. 16, 2026
Ozarks Farm Stop remains open after car crashes into building
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.